dTAGV-1 (CAS: 2624313-15-9) is a potent degrader targeting FKBP12F36V fusion proteins. It functions as a PROTAC, combining a ligand for the mutated FKBP12, a linker, and a ligand for von Hippel-Lindau (VHL). dTAGV-1 induces strong, selective degradation of FKBP12F36V proteins, working both in vitro and in vivo.
Applications:
- Targeted Protein Degradation:
Degrades FKBP12F36V fusion proteins, giving researchers precise control over protein levels. This makes it essential for studying protein functions in cells. - Drug Discovery and Development:
Helps selectively remove proteins, offering insights into potential therapeutic targets. It aids in developing treatments for diseases like cancer and immune disorders. - Functional Genomics:
Vital in functional genomics. It allows researchers to study how protein removal affects cell behavior and function.
Conclusion:
dTAGV-1 effectively degrades FKBP12F36V fusion proteins. Its ability to work both in vitro and in vivo makes it a powerful tool for protein research, drug discovery, and exploring new therapies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
